

Platelet Factor 4 Complexed to Heparin Is the Target for Heparin-Induced Thrombocytopenia

Thrombosis and Haemostasis

68, 095-096

DOI: 10.1055/s-0038-1656329

Citation Report

#	ARTICLE	IF	CITATIONS
1	Heparin-Associated Thrombocytopenia: No Association of Immune Response with HLA. Vox Sanguinis, 1993, 65, 151-153.	1.5	16
2	Heparin-associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides. British Journal of Haematology, 1993, 84, 711-716.	2.5	86
3	Mechanisms of Drug-Induced Immunologically Mediated Cytopenias. Transfusion Medicine Reviews, 1993, 7, 215-229.	2.0	43
4	Laboratory Investigation of Drug-Induced Immune Thrombocytopenias. Transfusion Medicine Reviews, 1993, 7, 275-287.	2.0	27
5	Drugs affecting blood coagulation and hemostasis. Side Effects of Drugs Annual, 1993, , 407-412.	0.6	0
6	Laboratory Monitoring of New Antithrombotic Drugs. Clinics in Laboratory Medicine, 1994, 14, 825-846.	1.4	7
7	Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood, 1994, 83, 3232-3239.	1.4	365
8	Pentosan-induced thrombocytopenia: support for an immune complex mechanism. British Journal of Haematology, 1994, 88, 803-808.	2.5	38
9	Heparin-induced thrombocytopenia and antithrombotic therapy. Lancet, The, 1994, 344, 1296.	13.7	21
10	Autoimmune Thrombocytopenia Purpura. BioDrugs, 1994, 1, 348-357.	0.7	4
11	Drugs affecting blood coagulation and fibrinolysis. Side Effects of Drugs Annual, 1994, , 366-369.	0.6	0
12	Heparin: Mechanism of Action, Pharmacokinetics, Dosing Considerations, Monitoring, Efficacy, and Safety. Chest, 1995, 108, 258S-275S.	0.8	396
13	Heparin-induced thrombocytopenia: an improved method of detection based on lumi-aggregometry. British Journal of Haematology, 1995, 91, 173-177.	2.5	55
14	Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran). British Journal of Haematology, 1995, 91, 736-738.	2.5	48
15	Single amino acid mutation of FC β 3 receptor is associated with the development of heparin-induced thrombocytopenia. British Journal of Haematology, 1995, 91, 761-766.	2.5	114
16	Annotation. British Journal of Haematology, 1995, 89, 431-439.	2.5	254
17	Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. American Journal of Hematology, 1995, 50, 20-25.	4.1	118
18	Heparin-induced thrombocytopenia and fatal thrombosis in a patient with activated protein C resistance. American Journal of Hematology, 1995, 50, 292-295.	4.1	12

#	ARTICLE	IF	CITATIONS
19	Diagnosis, treatment and pathophysiology of autoimmune thrombocytopenias. Critical Reviews in Oncology/Hematology, 1995, 20, 271-296.	4.4	22
20	State-of-the-Art Review: Usefulness of Laboratory Techniques for Evaluating Antithrombotic Efficacy of New Therapeutic Strategies. Clinical and Applied Thrombosis/Hemostasis, 1995, 1, 243-259.	1.7	3
21	Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin. New England Journal of Medicine, 1995, 332, 1330-1336.	27.0	2,664
22	COAGULATION DISORDERS IN CANCER. Hematology/Oncology Clinics of North America, 1996, 10, 457-484.	2.2	80
23	A 14-year study of heparin-induced thrombocytopenia. American Journal of Medicine, 1996, 101, 502-507.	1.5	872
24	Platelet binding of IgG from patients with heparin-induced thrombocytopenia. Translational Research, 1996, 127, 435-442.	2.3	49
25	Heparin-induced thrombocytopenia in hemodialysis patients. American Journal of Kidney Diseases, 1996, 28, 82-85.	1.9	174
26	Heparin-induced thrombocytopenia. Journal of Cardiothoracic and Vascular Anesthesia, 1996, 10, 521-530.	1.3	40
27	Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood, 1996, 88, 410-416.	1.4	240
28	Heparin as a cause of thrombus progression. European Journal of Pediatrics, 1996, 155, 11-14.	2.7	41
29	Pentosan polysulfate-induced thrombocytopenia: a case diagnosed with an ELISA test used for heparin-induced thrombocytopenia. Annals of Hematology, 1996, 73, 51-52.	1.8	7
30	Heparin-induced thrombocytopenia: What the serologists have taught us. Translational Research, 1996, 128, 346-348.	2.3	10
31	Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes. Translational Research, 1996, 128, 376-383.	2.3	173
32	Heparin-induced thrombocytopenia: Understanding improves but questions remain. Translational Research, 1996, 127, 418-419.	2.3	12
33	Heparin induced thrombocytopenia. European Journal of Vascular and Endovascular Surgery, 1996, 11, 260-269.	1.5	13
34	Heparin-Induced thrombocytopenia: IgG-Mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-Induced thrombocytopenia. Transfusion Medicine Reviews, 1996, 10, 249-258.	2.0	104
35	Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin. , 1996, 52, 90-95.		108
36	Heparin-induced thrombocytopenia: an under-diagnosed syndrome?. Platelets, 1997, 8, 65-82.	2.3	3

#	ARTICLE	IF	CITATIONS
37	Heparin-Induced Thrombocytopenia: Prevalence in a Large Cohort of Patients and Confirmed Role of PF4/Heparin Complex as the Main Antigen for Antibodies. Clinical and Applied Thrombosis/Hemostasis, 1997, 3, 203-209.	1.7	4
39	Heparin-associated Thrombocytopenia and Thrombosis. Anesthesiology, 1997, 87, 667-675.	2.5	44
40	Heparin-Induced Thrombocytopenia. Drug Safety, 1997, 17, 325-341.	3.2	91
41	Danaparoid. Drugs, 1997, 54, 903-924.	10.9	100
42	Cytokines, Adhesion Molecules, Antiendothelial Cell Autoantibodies and Vascular Disease. Cardiovascular Pathology, 1997, 6, 61-78.	1.6	12
43	Diagnosis of heparin-induced thrombocytopenia in the vascular surgery patient. Surgery, 1997, 121, 419-424.	1.9	18
44	EFFICACY OF PENTASACCHARIDE IN A DOG MODEL OF HEMODIALYSIS. Thrombosis Research, 1997, 88, 159-170.	1.7	7
45	Effective Anticoagulation by Argatroban During Coronary Stent Implantation in a Patient with Heparin-Induced Thrombocytopenia. Thrombosis Research, 1997, 88, 499-502.	1.7	8
46	Failure of low dosage thrombolytic therapy with streptokinase to treat heparin-induced thrombocytopenic-thrombotic syndrome. International Journal of Cardiology, 1997, 62, 87-89.	1.7	2
47	Management of Heparin-Induced Thrombocytopenia and Heparin-Induced Thrombocytopenia and Thrombosis Syndrome. Clinical and Applied Thrombosis/Hemostasis, 1997, 3, S53-S63.	1.7	9
48	The need for improved diagnosis of heparin-induced thrombocytopenia. Translational Research, 1997, 130, 242-244.	2.3	2
49	Activation of platelets by sera containing igg1 heparin-dependent antibodies: an explanation for the predominance of the FcγR1a low responder (his131) gene in patients with heparin-induced thrombocytopenia. Translational Research, 1997, 130, 278-284.	2.3	88
50	Erfolgreiche Behandlung einer Heparin-induzierten Thrombo-zytopenie Typ II im Kindesalter mit rekombinantem Hirudin. Monatsschrift Fur Kinderheilkunde, 1997, 145, 606-612.	0.1	28
51	Pathogenicity of human anti-platelet factor 4 (PF4)/heparin in vivo : generation of mouse anti-PF4/heparin and induction of thrombocytopenia by heparin. Clinical and Experimental Immunology, 1997, 108, 333-339.	2.6	31
52	Characterization of the humoral immune response in heparin-induced thrombocytopenia. , 1997, 54, 196-201.		103
53	High-dose intravenous gamma-globulins for heparin-induced thrombocytopenia: a prompt response. Journal of Clinical Immunology, 1998, 18, 330-334.	3.8	32
54	12 Heparin-induced thrombocytopenia: diagnostic tests and biological mechanisms. Best Practice and Research: Clinical Haematology, 1998, 11, 447-460.	1.1	12
55	13 Heparin-induced thrombocytopenia: pathophysiology and clinical concerns. Best Practice and Research: Clinical Haematology, 1998, 11, 461-474.	1.1	7

#	ARTICLE	IF	CITATIONS
56	Heparin-Induced Thrombocytopenia and Thrombosis. Journal of the American College of Surgeons, 1998, 186, 76-91.	0.5	27
57	Simultaneous binding of heparin and platelet factor-4 to platelets: Further insights into the mechanism of heparin-induced thrombocytopenia. , 1998, 58, 24-30.		45
58	Heparininduzierte Thrombozytopenie vom Typ II bei einem Patienten mit biventrikulärem Unterstützungssystem. Zeitschrift Fur Herz-, Thorax- Und Gefasschirurgie, 1998, 12, 140-143.	0.0	0
60	Heparin-induced thrombocytopenia and thrombosis. Clinical Reviews in Allergy and Immunology, 1998, 16, 237-247.	6.5	20
61	Low-molecular-weight heparin-induced skin necrosis. Annals of Hematology, 1998, 77, 127-130.	1.8	11
62	Anti-CD36 autoantibodies in thrombotic thrombocytopenic purpura and other thrombotic disorders: identification of an 85kD form of CD36 as a target antigen. British Journal of Haematology, 1998, 103, 849-857.	2.5	37
63	Anti-CD36 autoantibodies in thrombotic thrombocytopenic purpura and other thrombotic disorders: identification of an 85kD form of CD36 as a target antigen. British Journal of Haematology, 1998, 102, 849-857.	2.5	0
64	Les thrombopÃ©nies induites par l'hÃ©parine Physiopathologie et thÃ©rapeutique Conduite Ã tenir en chirurgie cardiaque. IRBM News, 1998, 20, 42-46.	0.0	0
65	Indications for therapeutic platelet transfusions. Blood Reviews, 1998, 12, 227-233.	5.7	11
66	Platelet Receptors for the Complement Component C1q: Implications for Hemostasis and Thrombosis. Immunobiology, 1998, 199, 239-249.	1.9	52
68	Peptide LSARLAF Activates Î±IIbÎ²3 on Resting Platelets and Causes Resting Platelet Aggregate Formation Without Platelet Shape Change. Thrombosis Research, 1998, 89, 31-40.	1.7	18
69	Platelet Count, Anti-Heparin/Platelet Factor 4 Antibodies and Tissue Factor Pathway Inhibitor Plasma Antigen Level in Chronic Dialysis. Thrombosis Research, 1998, 89, 115-122.	1.7	57
70	Cardiopulmonary bypass with danaparoid sodium and ancrod in heparin-induced thrombocytopenia. Annals of Thoracic Surgery, 1998, 66, 567-569.	1.3	17
71	Heparin-Induced Thrombocytopenia. Journal of the American College of Cardiology, 1998, 31, 1449-1459.	2.8	198
72	Reduced morbidity and mortality rates of the heparin-induced thrombocytopenia syndrome. Journal of Vascular Surgery, 1998, 27, 309-316.	1.1	48
73	Glycoprotein IIb/IIIa antagonists: Potential induction and detection of drug-dependent antiplatelet antibodies. American Heart Journal, 1998, 135, S152-S159.	2.7	24
74	The incidence of heparin-induced antibodies in patients undergoing vascular surgery: A prospective study. Journal of Vascular Surgery, 1998, 28, 439-445.	1.1	23
75	HEPARIN-INDUCED THROMBOCYTOPENIA, PARADOXICAL THROMBOEMBOLISM, AND OTHER SIDE EFFECTS OF HEPARIN THERAPY. Medical Clinics of North America, 1998, 82, 635-658.	2.5	83

#	ARTICLE	IF	CITATIONS
76	Two populations of endothelial cell antibodies cross-react with heparin. <i>Lupus</i> , 1998, 7, 86-94.	1.6	24
77	Anti-heparin antibodies: part of the repertoire of anti-endothelial cell antibodies (AECA). <i>Lupus</i> , 1998, 7, 68-72.	1.6	14
78	The First Report of Successful Carotid Stent Implant Using Argatroban Anticoagulation in a Patient with Heparin-Induced Thrombocytopenia and Thrombosis Syndrome. <i>Angiology</i> , 1998, 49, 61-67.	1.8	22
79	Antibody-mediated thrombosis: Relation to the antiphospholipid syndrome. <i>Lupus</i> , 1998, 7, 63-66.	1.6	7
80	Heparin and Low-Molecular-Weight Heparin. <i>Chest</i> , 1998, 114, 489S-510S.	0.8	679
81	Skin Necrosis at the Injection Site Induced by Low-Molecular-Weight Heparin: Case Report and Review. <i>Dermatology</i> , 1998, 196, 264-265.	2.1	24
82	Heparin-induced thrombocytopenia. <i>Postgraduate Medicine</i> , 1998, 103, 169-178.	2.0	21
83	Prevalence of Heparin-Induced PF4-Heparin Antibodies in Hemodialysis Patients. <i>Nephron</i> , 1998, 79, 245-246.	1.8	42
84	Adenosine Diphosphate (ADP) and ADP Receptor Play a Major Role in Platelet Activation/Aggregation Induced by Sera From Heparin-Induced Thrombocytopenia Patients. <i>Blood</i> , 1998, 91, 549-554.	1.4	99
85	Antibodies From Patients With Heparin-Induced Thrombocytopenia/Thrombosis Recognize Different Epitopes on Heparin: Platelet Factor 4. <i>Blood</i> , 1998, 91, 916-922.	1.4	110
86	Heparin-Induced Thrombocytopenia: New Insights Into the Impact of the Fc γ RIIa-R-H131 Polymorphism. <i>Blood</i> , 1998, 92, 1526-1531.	1.4	176
87	Defining an Antigenic Epitope on Platelet Factor 4 Associated With Heparin-Induced Thrombocytopenia. <i>Blood</i> , 1998, 92, 3250-3259.	1.4	125
88	Heparin-induced Thrombocytopenia: Towards Consensus. <i>Thrombosis and Haemostasis</i> , 1998, 79, 1-7.	3.4	595
89	Heparin-Induced Thrombocytopenia: Historical Review. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, S2-S6.	1.7	5
90	First Workshop for Detection of Heparin-induced Antibodies: Validation of the Heparin-induced Platelet-activation Test (HIPA) in Comparison with a PF4/Heparin ELISA. <i>Thrombosis and Haemostasis</i> , 1999, 81, 625-629.	3.4	161
91	Heparin-Induced Thrombocytopenic Potential of GAG and Non-GAG-Based Antithrombotic Agents. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, S56-S62.	1.7	10
92	Generation and Pathogenicity of Anti-Platelet Factor 4 Antibodies: Diagnostic Implications. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, S28-S31.	1.7	14
93	Vascular Damage Correlates between Heparin-Induced Thrombocytopenia and the Antiphospholipid Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, S76-S84.	1.7	12

#	ARTICLE	IF	CITATIONS
94	Complexes of Heparin and Platelet Factor 4 Specifically Stimulate T Cells From Patients With Heparin-Induced Thrombocytopenia/Thrombosis. <i>Blood</i> , 1999, 94, 208-215.	1.4	48
95	Antibodies to Platelet Factor 4â€“Heparin After Cardiopulmonary Bypass in Patients Anticoagulated With Unfractionated Heparin or a Low-Molecular-Weight Heparin. <i>Circulation</i> , 1999, 99, 2530-2536.	1.6	325
97	Recombinant Hirudin (Lepirudin) Provides Safe and Effective Anticoagulation in Patients With Heparin-Induced Thrombocytopenia. <i>Circulation</i> , 1999, 99, 73-80.	1.6	505
98	Synthetic Pentasaccharides Do Not Cause Platelet Activation by Antiheparin-Platelet Factor 4 Antibodies. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, 259-266.	1.7	69
99	HEPARIN-INDUCED THROMBOCYTOPENIA: A Ten-Year Retrospective. <i>Annual Review of Medicine</i> , 1999, 50, 129-147.	12.2	128
100	Platelet microparticles: a wide-angle perspective. <i>Critical Reviews in Oncology/Hematology</i> , 1999, 30, 111-142.	4.4	275
101	Association of heparinâ€“induced skin lesions, intracutaneous tests, and heparinâ€“induced IgG. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1999, 54, 473-477.	5.7	66
102	Heparin-induced thrombocytopenia. <i>Blood Reviews</i> , 1999, 13, 1-7.	5.7	17
103	Further characterization of antibody and antigen in heparin-induced thrombocytopenia. <i>British Journal of Haematology</i> , 1999, 107, 303-309.	2.5	52
106	Newer Strategies for the Treatment of Heparin-Induced Thrombocytopenia. <i>Pharmacotherapy</i> , 1999, 19, 181-195.	2.6	49
107	Determination of heparin-induced IgG antibody by fluorescence-linked immunofiltration assay (FLIFA). <i>Journal of Immunological Methods</i> , 1999, 222, 93-99.	1.4	16
108	PERIOPERATIVE ANTICOAGULATION AND THROMBOLYSIS IN CONGENITAL AND ACQUIRED COAGULOPATHIES. <i>Anesthesiology Clinics</i> , 1999, 17, 923-958.	1.4	4
109	Ventricular thrombus and subarachnoid bleeding during support with ventricular assist devices. <i>Annals of Thoracic Surgery</i> , 1999, 67, 1778-1780.	1.3	11
110	Outpatient treatment of deep vein thrombosis: translating clinical trials into practice. <i>American Journal of Medicine</i> , 1999, 106, 660-669.	1.5	36
111	Laboratory Diagnosis of Heparin-Induced Thrombocytopenia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, S21-S27.	1.7	36
112	Functional Heterogeneity of Antiheparin-Platelet Factor 4 Antibodies: Implications in the Pathogenesis of the HIT Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, S32-S37.	1.7	16
113	Efficacy and Safety of Danaparoid Sodium (ORG 10172) in Critically Ill Patients With Heparin-Associated Thrombocytopenia. <i>Chest</i> , 1999, 115, 1616-1620.	0.8	83
114	Clinical Usefulness of Combined use of Platelet Aggregation Test and Anti PF4-H. Antibodies Elisa test for the Diagnosis of Heparin Induced Thrombocytopenia. <i>Hematology</i> , 1999, 4, 367-372.	1.5	11

#	ARTICLE	IF	CITATIONS
115	Neurologic complications in immune-mediated heparin-induced thrombocytopenia. <i>Neurology</i> , 2000, 54, 1240-1245.	1.1	58
116	ET gets HIT – thrombocytotic heparin-induced thrombocytopenia (HIT) in a patient with essential thrombocythemia (ET). <i>Blood Coagulation and Fibrinolysis</i> , 2000, 11, 663-667.	1.0	17
117	Determination of serotonin release from platelets by enzyme immunoassay in the diagnosis of heparin-induced thrombocytopenia. <i>British Journal of Haematology</i> , 2000, 109, 182-186.	2.5	36
118	Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation. <i>British Journal of Haematology</i> , 2000, 109, 336-341.	2.5	66
119	Heparin-induced skin necrosis. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2000, 107, 1315-1316.	2.3	13
120	Heparin-induced thrombocytopenia. <i>Journal of Vascular Nursing</i> , 2000, 18, 54-58.	0.7	0
121	Heparin induced thrombocytopenia and thrombosis. <i>Progress in Cardiovascular Diseases</i> , 2000, 42, 247-260.	3.1	19
122	Evaluation and Management of Drug-Induced Thrombocytopenia in the Acutely Ill Patient. <i>Pharmacotherapy</i> , 2000, 20, 292-307.	2.6	66
123	Key references: anticoagulants and coagulation monitoring. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 9, 69-76.	2.1	0
124	Heparin-induced thrombocytopenia and its treatment. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 9, 29-35.	2.1	16
125	Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 10, 13-20.	2.1	66
126	Laboratory testing for heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 10, 35-45.	2.1	58
127	Pulmonary embolus after coronary artery bypass surgery: A review of the literature. <i>Clinical Cardiology</i> , 2000, 23, 637-644.	1.8	75
128	Complications during Inpatient Thrombosis Prophylaxis – Experience from 40 Patients with Heparin-Induced Thrombocytopenia Type II (HIT II). <i>European Journal of Trauma and Emergency Surgery</i> , 2000, 26, 226-232.	0.3	0
129	Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. <i>Blood</i> , 2000, 95, 1533-1540.	1.4	112
130	Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. <i>Blood</i> , 2000, 96, 188-194.	1.4	190
131	Impact of the patient population on the risk for heparin-induced thrombocytopenia. <i>Blood</i> , 2000, 96, 1703-1708.	1.4	976
132	Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. <i>Blood</i> , 2000, 96, 2373-2378.	1.4	220

#	ARTICLE	IF	CITATIONS
133	Characteristics of Heparin-Induced Platelet Aggregates in Chronic Hemodialysis with Long-Term Heparin Use. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2000, 30, 249-257.	0.3	5
134	State-of-the-Art Review : Heparin-Induced Thrombocytopenia: A Critical Risk/Benefit Analysis of Patients in Intensive Care Treated With R-Hirudin. Clinical and Applied Thrombosis/Hemostasis, 2000, 6, 151-156.	1.7	4
135	Investigation of a platelet factor 4 polymorphism on the immune response in patients with heparin-induced thrombocytopenia. Platelets, 2000, 11, 23-27.	2.3	14
136	Endovascular Repair of an Extracranial Internal Carotid Artery Aneurysm Complicated by Heparin-Induced Thrombocytopenia and Thrombosis. Journal of Endovascular Therapy, 2000, 7, 353-358.	1.5	25
137	Antiphospholipid Syndrome and Heparin-induced Thrombocytopenia: Update on Similarities and Differences. Journal of Autoimmunity, 2000, 15, 265-268.	6.5	25
138	In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytopenia type II undergoing cardiovascular surgery. Journal of Clinical Anesthesia, 2000, 12, 324-327.	1.6	26
139	A New Therapeutic Option by Subcutaneous Recombinant Hirudin in Patients with Heparin-induced Thrombocytopenia Type II. Thrombosis Research, 2000, 99, 325-334.	1.7	34
140	Human Anti-heparin-Platelet Factor 4 Antibodies Are Capable of Activating Primate Platelets. Thrombosis Research, 2000, 100, 47-54.	1.7	3
141	Very Low Platelet Counts in Post-transfusion Purpura Falsely Diagnosed as Heparin-induced Thrombocytopenia. Thrombosis Research, 2000, 100, 115-125.	1.7	70
142	A Prospective Study on the Incidence and Clinical Relevance of Heparin-Induced Antibodies in Patients after Vascular Surgery. Thrombosis Research, 2000, 97, 387-393.	1.7	63
143	Heparin-Induced Thrombocytopenia. Drugs and Aging, 2000, 16, 351-364.	2.7	19
144	Temporal Aspects of Heparin-Induced Thrombocytopenia. New England Journal of Medicine, 2001, 344, 1286-1292.	27.0	925
145	Identification of T cells responding to a self-protein modified by an external agent. Human Immunology, 2001, 62, 113-124.	2.4	18
146	Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia. Annals of Thoracic Surgery, 2001, 71, 678-683.	1.3	60
147	Heparin-induced thrombocytopenia: bovine versus porcine heparin in cardiopulmonary bypass surgery. Annals of Thoracic Surgery, 2001, 71, 1920-1924.	1.3	34
148	BLEEDING AND THROMBOTIC COMPLICATIONS IN CRITICALLY ILL PATIENTS WITH CANCER. Critical Care Clinics, 2001, 17, 599-622.	2.6	25
149	Delayed thrombocytopenia following abciximab therapy. International Journal of Cardiovascular Interventions, 2001, 4, 151-155.	0.5	12
150	Improved Laboratory Confirmation of Heparin-Induced Thrombocytopenia Type II. American Journal of Clinical Pathology, 2001, 115, 432-438.	0.7	14

#	ARTICLE	IF	CITATIONS
151	The role of platelet factor 4 in platelet aggregation induced by the antibodies implicated in heparin-induced thrombocytopenia. <i>Blood Coagulation and Fibrinolysis</i> , 2001, 12, 511-520.	1.0	13
152	Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through Fc γ RIIA. <i>Blood</i> , 2001, 98, 2442-2447.	1.4	193
153	Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. <i>Blood</i> , 2001, 97, 3300-3302.	1.4	191
154	Delayed-Onset Heparin-Induced Thrombocytopenia and Thrombosis. <i>Annals of Internal Medicine</i> , 2001, 135, 502.	3.9	429
155	Mechanism and Clinical Presentation of Heparin-Induced Thrombocytopenia. <i>Hemodialysis International</i> , 2001, 5, 74-80.	0.9	3
156	Anticoagulation for acute coronary syndromes and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. <i>Current Cardiology Reports</i> , 2001, 3, 362-370.	2.9	9
157	Anti-PF4-heparin immunoglobulin G is the major class of heparin-induced thrombocytopenia antibody: findings of an enzyme-linked immunofiltration assay using membrane-bound hPF4-heparin. <i>British Journal of Haematology</i> , 2001, 112, 69-75.	2.5	13
158	Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. <i>British Journal of Haematology</i> , 2001, 113, 886-890.	2.5	92
159	Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: Case reports. <i>Catheterization and Cardiovascular Interventions</i> , 2001, 52, 468-472.	1.7	26
160	Heparin induced thrombocytopenia: prevalence in India. <i>American Journal of Hematology</i> , 2001, 68, 216-217.	4.1	2
161	Association of eptifibatide and acute profound thrombocytopenia. <i>American Journal of Cardiology</i> , 2001, 88, 428-431.	1.6	62
162	Laboratory diagnosis of heparin-induced thrombocytopenia type II after clearance of platelet factor 4/heparin complex. <i>Translational Research</i> , 2001, 137, 408-413.	2.3	19
163	Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. <i>Translational Research</i> , 2001, 138, 22-31.	2.3	129
164	Heparin antibodies and thromboembolism in heparin-coated and noncoated ventricular assist devices. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2001, 121, 331-335.	0.8	41
165	DRUG-INDUCED AND DRUG-DEPENDENT IMMUNE THROMBOCYTOPENIAS. <i>Reviews in Clinical and Experimental Hematology</i> , 2001, 5, 166-200.	0.1	49
166	Glucosamine sulfate does not crossreact with the antibodies of patients with heparin-induced thrombocytopenia. <i>European Journal of Haematology</i> , 2001, 66, 195-199.	2.2	10
167	Heparin induced thrombocytopenia thrombosis (HIT/T) syndrome: diagnosis and treatment. <i>Journal of Clinical Pathology</i> , 2001, 54, 272-274.	2.0	62
168	Guide to Anticoagulant Therapy: Heparin. <i>Circulation</i> , 2001, 103, 2994-3018.	1.6	451

#	ARTICLE	IF	CITATIONS
169	Guide to Anticoagulant Therapy: Heparin. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, E9-9.	2.4	50
170	Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety. <i>Chest</i> , 2001, 119, 64S-94S.	0.8	1,275
171	Use of a Low-Molecular-Weight Heparinoid (Danaparoid Sodium) for Continuous Renal Replacement Therapy in Intensive Care Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2001, 7, 300-304.	1.7	34
172	Heparin-Induced Thrombocytopenia-Associated Thrombosis in Pediatric Intensive Care Patients. <i>Pediatrics</i> , 2002, 109, e10-e10.	2.1	106
173	Development of a High-Pressure Liquid Chromatography Method for Diagnosis of Heparin-Induced Thrombocytopenia. <i>American Journal of Clinical Pathology</i> , 2002, 117, 900-904.	0.7	10
174	Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. <i>International Immunology</i> , 2002, 14, 121-129.	4.0	118
175	Risk Factors and Long-term Follow-up of Patients with the Immune Type of Heparin-Induced Thrombocytopenia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2002, 8, 347-352.	1.7	11
176	Insights from mouse models of heparin-induced thrombocytopenia and thrombosis. <i>Current Opinion in Hematology</i> , 2002, 9, 395-400.	2.5	21
177	Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. <i>Blood</i> , 2002, 99, 1230-1236.	1.4	117
178	Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. <i>Thrombosis Research</i> , 2002, 105, 117-123.	1.7	44
179	Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies. <i>Thrombosis Research</i> , 2002, 108, 49-55.	1.7	31
180	Heparin-induced thrombocytopenia: a common complication in cardiac transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2002, 21, 1283-1289.	0.6	46
181	Pathogenesis of heparin-induced thrombocytopenia and thrombosis. <i>Autoimmunity Reviews</i> , 2002, 1, 125-132.	5.8	33
182	Allergies aux héparines. <i>Revue Française D'allergologie Et D'immunologie Clinique</i> , 2002, 42, 97-103.	0.1	3
183	Effects of β_2 -glycoprotein I and monoclonal anticardiolipin antibodies in platelet interaction with subendothelium under flow conditions. <i>Arthritis and Rheumatism</i> , 2002, 46, 3283-3289.	6.7	20
184	Heparin-induced thrombocytopenia: Molecular pathogenesis. <i>International Journal of Hematology</i> , 2002, 76, 346-351.	1.6	4
185	The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. <i>British Journal of Haematology</i> , 2002, 116, 887-891.	2.5	85
186	Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia. <i>Journal of Internal Medicine</i> , 2002, 252, 149-154.	6.0	61

#	ARTICLE	IF	CITATIONS
187	Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. <i>British Journal of Haematology</i> , 2002, 118, 1137-1142.	2.5	111
188	Mechanisms of Action of IVIg: Physiology of Fc Receptors. <i>Vox Sanguinis</i> , 2002, 83, 57-63.	1.5	5
189	Heparin-induced thrombocytopenia: an overview. <i>Blood Reviews</i> , 2002, 16, 77-80.	5.7	94
190	Obstinate thrombosis during percutaneous coronary intervention in a case with heparin-induced thrombocytopenia with thrombosis syndrome successfully treated by argatroban anticoagulant therapy. <i>Catheterization and Cardiovascular Interventions</i> , 2003, 59, 351-354.	1.7	17
191	HEPARIN-INDUCED THROMBOCYTOPENIA IN DIALYSIS: The Pathophysiology of Immune-mediated Heparin-induced Thrombocytopenia. <i>Seminars in Dialysis</i> , 2003, 16, 54-60.	1.3	48
192	Heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1471-1478.	3.8	213
193	Does negative heparin-platelet factor 4 enzyme-linked immunosorbent assay effectively exclude heparin-induced thrombocytopenia?. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1844-1845.	3.8	21
194	Heparin-induced thrombocytopenia: pathogenesis and management. <i>British Journal of Haematology</i> , 2003, 121, 535-555.	2.5	492
195	Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other adverse effects of heparin-type therapy. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 259-282.	2.2	16
196	Benefit-Risk Assessment of Treatments for Heparin-Induced Thrombocytopenia. <i>Drug Safety</i> , 2003, 26, 625-641.	3.2	28
197	Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. <i>American Journal of Medicine</i> , 2003, 114, 528-536.	1.5	72
198	A positive in vitro assay is required to diagnose heparin-induced thrombocytopenia. <i>Medical Clinics of North America</i> , 2003, 87, 1215-1224.	2.5	4
199	HIT/HITT and alternative anticoagulation: current concepts. <i>British Journal of Anaesthesia</i> , 2003, 90, 676-685.	3.4	40
200	Acute Myocardial Infarction Caused by Delayed Heparin-Induced Thrombocytopenia and Acute Immunoreaction due to Re-exposure to Heparin in a Systemic Lupus Erythematosus Patient with HIT Antibodies. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 341-346.	1.7	3
201	On the Prophylactic and Therapeutic Use of Danaparoid Sodium (Orgaran®) in Patients With Heparin-Induced Thrombocytopenia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 25-32.	1.7	12
202	Laboratory Diagnosis of Heparin-Induced Thrombocytopenia and Monitoring of Alternative Anticoagulants. <i>Vaccine Journal</i> , 2003, 10, 731-740.	3.1	26
203	Platelet-Endothelial Interactions: Sepsis, HIT, and Antiphospholipid Syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2003, 2003, 497-519.	2.5	127
204	Platelet Function and Immune Response. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, S19-S23.	0.6	8

#	ARTICLE	IF	CITATIONS
205	Antithrombotic Drugs for the Treatment of Heparin-Induced Thrombocytopenia. , 2004, 93, 61-82.		7
206	Platelet activation induced by human antibodies to interleukin-8. Blood, 2003, 101, 1419-1421.	1.4	91
207	The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood, 2003, 101, 2955-2959.	1.4	271
208	Laboratory Methods for Heparin-Induced Thrombocytopenia. , 2004, 93, 83-94.		1
209	Hypercoagulability as a Cause of Stroke in Adults. Southern Medical Journal, 2003, 96, 350-353.	0.7	16
210	Anti-Heparin-Platelet Factor 4 Antibody is a Risk Factor for Vascular Access Obstruction in Patients Undergoing Hemodialysis. Journal of Korean Medical Science, 2003, 18, 69.	2.5	9
211	Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems. Thrombosis and Haemostasis, 2004, 91, 276-282.	3.4	50
212	Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention. Chest, 2004, 126, 311S-337S.	0.8	766
213	Heparin-induced thrombocytopenia in neurologic disease treated with unfractionated heparin. Neurology, 2004, 62, 657-659.	1.1	39
215	Thrombocytopenia due to acute venous thromboembolism and its role in expanding the differential diagnosis of heparin-induced thrombocytopenia. American Journal of Hematology, 2004, 76, 69-73.	4.1	32
216	Heparin is much more than just an anticoagulant. Journal of Cardiothoracic and Vascular Anesthesia, 2004, 18, 93-100.	1.3	21
218	Heparin-Induced Thrombocytopenia. International Anesthesiology Clinics, 2004, 42, 27-43.	0.8	19
219	Treatment of Heparin-Induced Thrombocytopenia. Archives of Internal Medicine, 2004, 164, 361.	3.8	184
220	Unfractionated heparin compared with low-molecular-weight heparin as related to heparin-induced thrombocytopenia. Current Opinion in Pulmonary Medicine, 2005, 11, 385-391.	2.6	29
221	New Approaches to the Diagnosis of Heparin-Induced Thrombocytopenia. Chest, 2005, 127, 35S-45S.	0.8	145
222	Heparin-induced thrombocytopenia in the pediatric intensive care unit population. Pediatric Critical Care Medicine, 2005, 6, 216-219.	0.5	17
223	The Pathophysiology of Heparin-Induced Thrombocytopenia. Chest, 2005, 127, 9S-20S.	0.8	96
224	Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. Journal of Thrombosis and Haemostasis, 2005, 3, 2168-2175.	3.8	53

#	ARTICLE	IF	CITATIONS
225	Heparin-induced thrombocytopenia antibody and the pathogenesis of thrombotic microangiopathy after stem cell transplantation. <i>Clinical Transplantation</i> , 2005, 19, 418-422.	1.6	5
226	Low-molecular-weight heparin-induced skin necrosis: a potential association with pre-existent hypercoagulable states. <i>International Journal of Dermatology</i> , 2005, 44, 964-966.	1.0	15
227	Role of platelet factor 4-heparin complex antibody (HIT antibody) in the pathogenesis of thrombotic episodes in patients on hemodialysis. <i>Hemodialysis International</i> , 2005, 9, S2-S7.	0.9	28
228	A rare case of HITTS following prophylactic LMWH therapy in a blunt trauma victim. <i>Injury</i> , 2005, 36, 347-351.	1.7	1
229	Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need?. <i>Translational Research</i> , 2005, 146, 341-346.	2.3	261
230	Prevalence of heparin-induced antibodies in patients with chronic renal failure undergoing hemodialysis. <i>Journal of Clinical Laboratory Analysis</i> , 2005, 19, 189-195.	2.1	35
231	Thrombocytopenic conditions—autoimmunity and hypercoagulability: Commonalities and differences in ITP, TTP, HIT, and APS. <i>American Journal of Hematology</i> , 2005, 80, 232-242.	4.1	38
232	Identification, Diagnosis and Treatment of Heparin-induced Thrombocytopenia and Thrombosis: A Registry of Prolonged Heparin Use and Thrombocytopenia among Hospitalized Patients with and without Cardiovascular Disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2005, 19, 11-19.	2.1	33
233	Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar. <i>Thrombosis Journal</i> , 2005, 3, 4.	2.1	12
235	Heparin-induced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines. <i>European Journal of Cardio-thoracic Surgery</i> , 2005, 27, 138-149.	1.4	22
236	Low-molecular-weight heparin-associated fat necrosis of the breast. <i>Age and Ageing</i> , 2005, 34, 193-194.	1.6	7
237	Heparin-induced thrombocytopenia in neurologic patients treated with low-molecular-weight heparin. <i>Neurology</i> , 2005, 64, 1285-1287.	1.1	24
238	Heparin-Induced Thrombocytopenia Complicating Support by the Berlin Heart. <i>ASAIO Journal</i> , 2005, 51, 820-825.	1.6	20
239	Mechanistic basis of heparin-induced thrombocytopenia. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2005, 17, 73-79.	0.6	29
240	Anticoagulation management and cardiac surgery in patients with heparin-induced thrombocytopenia. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2005, 17, 85-96.	0.6	25
241	Heparin-Induced Thrombocytopenia: An Iceberg Rising. <i>Mayo Clinic Proceedings</i> , 2005, 80, 988-990.	3.0	19
242	Association of Heparin-Dependent Antibodies and Adverse Outcomes in Hemodialysis Patients: A Population-Based Study. <i>Mayo Clinic Proceedings</i> , 2005, 80, 995-1000.	3.0	62
243	Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. <i>Blood</i> , 2005, 105, 131-138.	1.4	272

#	ARTICLE	IF	CITATIONS
244	Argatroban, a direct thrombin inhibitor for heparin-induced thrombocytopaenia: present and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 81-89.	1.8	8
245	Heparin-Induced Thrombocytopenia. <i>New England Journal of Medicine</i> , 2006, 355, 809-817.	27.0	560
246	Diagnosis and treatment of heparin-induced thrombocytopenia in neonates and children. <i>Thrombosis Research</i> , 2006, 118, 123-135.	1.7	79
247	Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. <i>Blood</i> , 2006, 107, 2346-2353.	1.4	234
248	Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. <i>Blood</i> , 2006, 108, 2937-2941.	1.4	259
250	ThrombopÃ©nies et thromboses induites par l'hÃ©parine: Un syndrome clinico-biologique sÃ©vÃ©re. <i>Revue Francophone Des Laboratoires</i> , 2006, 2006, 49-58.	0.0	1
251	Determination of serotonin release from platelets by HPLC and ELISA in the diagnosis of heparin-induced thrombocytopenia: comparison with reference method by [¹⁴ C]-serotonin release assay. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1136-1139.	3.8	21
253	Catastrophic thromboses and severe thrombocytopenia during heparin therapy in a patient with anti-phospholipid syndrome. <i>Clinical Rheumatology</i> , 2006, 25, 426-429.	2.2	7
254	Diagnosis and management of heparin-induced thrombocytopenia. <i>Canadian Journal of Anaesthesia</i> , 2006, 53, S123-S134.	1.6	11
255	Incidence and clinical significance of antiâ€”PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparinâ€”induced thrombocytopenia. <i>European Journal of Haematology</i> , 2006, 76, 420-426.	2.2	162
256	Testing for Heparin-Induced Thrombocytopenia Antibodies. <i>Transfusion Medicine Reviews</i> , 2006, 20, 259-272.	2.0	142
258	Heparin-induced thrombocytopenia and thrombosis. <i>American Journal of Hematology</i> , 2006, 81, 36-44.	4.1	68
259	HIT: Lessons Learned. Pathophysiology of Haemostasis and Thrombosis: <i>International Journal on Haemostasis and Thrombosis Research</i> , 2006, 35, 50-57.	0.3	25
260	Heparin-Induced Thrombocytopenia: Frequency and Pathogenesis. Pathophysiology of Haemostasis and Thrombosis: <i>International Journal on Haemostasis and Thrombosis Research</i> , 2006, 35, 37-45.	0.3	26
261	Heparin-Induced Thrombocytopenia: A Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 803-809.	2.7	145
262	Disseminated intravascular clotting associated with Fc-receptor IIa-mediated platelet activation in a patient with endocarditis after aortic valve replacement. <i>British Journal of Anaesthesia</i> , 2006, 97, 630-633.	3.4	4
263	Close Approximation of Two Platelet Factor 4 Tetramers by Charge Neutralization Forms the Antigens Recognized by HIT Antibodies. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 2386-2393.	2.4	156
264	A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 5471-5480.	7.0	92

#	ARTICLE	IF	CITATIONS
265	Incidence of Antiheparin-Platelet Factor 4 Antibodies and Heparin-Induced Thrombocytopenia in Turkish Patients Undergoing Cardiac Surgery. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2007, 13, 279-284.	1.7	4
266	Hgh prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin-induced thrombocytopenia. <i>Lupus</i> , 2007, 16, 79-83.	1.6	33
267	Heparin-Induced Thrombocytopenia. <i>Journal of Infusion Nursing</i> , 2007, 30, 232-240.	2.3	5
268	Endothelial cell damage in heparin-induced thrombocytopenia. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 317-320.	1.0	15
269	Heparin-Induced Thrombocytopenia Type II: A Serious Hazard in Preemptive Renal Transplantation: A Case Report. <i>Transplantation Proceedings</i> , 2007, 39, 3481-3484.	0.6	11
270	Spontaneous superior sagittal sinus thrombosis secondary to type II heparin-induced thrombocytopenia presenting as an acute subarachnoid hemorrhage. <i>Journal of Clinical Neuroscience</i> , 2007, 14, 890-895.	1.5	13
271	Drug-Induced Thrombocytopenia. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 685-696.	2.2	128
273	Heparin-induced thrombocytopenia: Impact of bovine versus porcine heparin in HIT pathogenesis. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 3312.	3.0	12
274	Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2007, 82, 276-282.	4.1	6
275	Attempts to make sense of the antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1-4.	3.8	13
276	Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1666-1673.	3.8	224
277	Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay results. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 26, 55-61.	2.1	35
278	A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 63, 65-74.	2.3	22
279	Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature. <i>Transfusion</i> , 2008, 48, 2128-2132.	1.6	55
280	Quantitative interpretation of optical density measurements using PF4-dependent enzyme immunoassays. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1304-1312.	3.8	333
281	An algorithm for resolving "indeterminate" test results in the platelet serotonin release assay for investigation of heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1595-1597.	3.8	24
282	Heparin-induced thrombocytopenia "therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 2160-2167.	3.8	68
283	Rivaroxaban "an oral, direct Factor Xa inhibitor" has potential for the management of patients with heparin-induced thrombocytopenia. <i>British Journal of Haematology</i> , 2008, 143, 92-99.	2.5	78

#	ARTICLE	IF	CITATIONS
284	Chapter 45 Hematological diseases and stroke. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 93, 887-934.	1.8	1
285	Lepirudin in the management of heparin-induced thrombocytopenia. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 1131-1141.	3.3	7
286	The Relationship Between the Antiphospholipid Syndrome and Heparin-Induced Thrombocytopenia. Hematology/Oncology Clinics of North America, 2008, 22, 1-18.	2.2	27
287	Heparin-platelet factor 4 antibodies are frequent after vascular surgery but are not a frequent cause of graft thrombosis or thrombocytopenia. Journal of Vascular Surgery, 2008, 48, 377-381.	1.1	6
288	Serologic Results in >1000 Patients With Suspected Heparin-Induced Thrombocytopenia. Clinical and Applied Thrombosis/Hemostasis, 2008, 14, 410-414.	1.7	11
289	Heparin induced thrombocytopenia with thrombosis: a two step process?. Hematology, 2008, 13, 181-182.	1.5	3
290	The Laboratory Diagnosis and Clinical Management of Patients with Heparin-Induced Thrombocytopenia: An Update. Seminars in Thrombosis and Hemostasis, 2008, 34, 086-096.	2.7	35
291	Heparin-induced thrombocytopenia: a historical perspective. Blood, 2008, 112, 2607-2616.	1.4	172
292	Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion. Blood, 2008, 112, 1091-1100.	1.4	71
293	Treatment and Prevention of Heparin-Induced Thrombocytopenia. Chest, 2008, 133, 340S-380S.	0.8	783
294	Urgent Cardiac Surgery in a Patient with a Remote History of Heparin-Induced Thrombocytopenia: Use of the Anti-PF4/Heparin ELISA Confirmatory Test. Anesthesia and Analgesia, 2008, 107, 379-381.	2.2	10
295	A prospective analysis of heparin-platelet factor 4 antibodies in pregnant women treated with the low-molecular-weight heparin, dalteparin. Blood Coagulation and Fibrinolysis, 2008, 19, 477-481.	1.0	6
296	The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thrombocytopenia and thrombosis caused by heparin flushes. Therapeutics and Clinical Risk Management, 2008, Volume 4, 653-657.	2.0	13
297	Heparin-Induced Thrombocytopenia: An Estimate of the Average Cost in the Hospital Setting in France. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 428-434.	1.7	15
298	ASH evidence-based guidelines: is the IgG-specific anti-PF4/heparin ELISA superior to the polyspecific ELISA in the laboratory diagnosis of HIT?. Hematology American Society of Hematology Education Program, 2009, 2009, 250-252.	2.5	28
299	The incidence of heparin-induced thrombocytopenia Type II in patients with subarachnoid hemorrhage treated with heparin versus enoxaparin. Journal of Neurosurgery, 2009, 110, 50-57.	1.6	15
300	Clinical relevance of heparin-PF4 complex antibody in DVT after total joint replacement. BMC Musculoskeletal Disorders, 2009, 10, 42.	1.9	4
301	Platelet and monocyte antigenic complexes in the pathogenesis of heparin-induced thrombocytopenia (HIT). Journal of Thrombosis and Haemostasis, 2009, 7, 249-252.	3.8	21

#	ARTICLE	IF	CITATIONS
302	Heparin-induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2009, 7, 9-12.	3.8	126
303	Danaparoid cross-reactivity with heparin-induced thrombocytopenia antibodies: report of 12 cases. Intensive Care Medicine, 2009, 35, 1449-1453.	8.2	22
304	Immune mechanisms in heparin-induced thrombocytopenia: no evidence for immunoglobulin M anti-idiotypic antibodies. Transfusion, 2009, 49, 1812-1818.	1.6	4
305	Antiphospholipid and anti-PF4 antibodies: an association affecting anti-PF4/heparin assay analysis. Journal of Thrombosis and Haemostasis, 2009, 7, 1067-1069.	3.8	7
306	Immunoassays are not created equal. Journal of Thrombosis and Haemostasis, 2009, 7, 1256-1259.	3.8	21
307	High levels of heparin-platelet factor 4 antibodies in patients with pseudothrombocytopenia: risk of misdiagnosis. Journal of Thrombosis and Haemostasis, 2009, 7, 1416-1418.	3.8	11
308	Thrombin generation and heparin-induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2009, 7, 1474-1481.	3.8	40
309	Heparin-induced thrombocytopenia: a renal perspective. Nature Reviews Nephrology, 2009, 5, 501-511.	9.6	51
310	Heparin-induced thrombocytopenia after implantation of a heparin-bonded polytetrafluoroethylene lower extremity bypass graft: A case report and plan for management. Journal of Vascular Surgery, 2009, 49, 1037-1040.	1.1	20
311	Cell-derived microparticles in haemostasis and vascular medicine. Thrombosis and Haemostasis, 2009, 101, 439-451.	3.4	359
312	Thrombotic Thrombocytopenic Purpura and Heparin-Induced Thrombocytopenia: Two Unique Causes of Life-Threatening Thrombocytopenia. Clinics in Laboratory Medicine, 2009, 29, 321-338.	1.4	17
313	Heparin-Induced Thrombocytopenia. Chest, 2009, 135, 1651-1664.	0.8	124
314	The temporal profile of the anti-PF4/heparin immune response. Blood, 2009, 113, 4970-4976.	1.4	109
315	Studies of the immune response in heparin-induced thrombocytopenia. Blood, 2009, 113, 4963-4969.	1.4	157
316	Treatment options in heparin-induced thrombocytopenia. Current Opinion in Hematology, 2010, 17, 424-431.	2.5	11
317	Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood, 2010, 116, 5021-5031.	1.4	134
318	Significance of quantitative measurement of heparin-induced platelet antibodies. European Journal of Haematology, 2010, 84, 169-174.	2.2	7
319	Heparin-induced thrombocytopenia: Current status and diagnostic challenges. American Journal of Hematology, 2010, 85, 700-706.	4.1	45

#	ARTICLE	IF	CITATIONS
320	Studies of the anti-platelet factor 4/heparin immune response: adapting the enzyme-linked immunosorbent spot assay for detection of memory B cells against complex antigens. <i>Transfusion</i> , 2010, 50, 32-39.	1.6	30
321	Postoperative platelet count profile: the most reliable tool for identifying patients with true heparin-induced thrombocytopenia after cardiac surgery. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 27-29.	3.8	30
322	Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 616-618.	3.8	27
323	Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 504-512.	3.8	51
325	Heparin-induced thrombocytopenia/Thrombosis: a clinico-pathological review. <i>East African Medical Journal</i> , 2010, 86, .	0.0	2
326	Immunobiology of Heparin-Induced Thrombocytopenia. <i>Current Topics in Microbiology and Immunology</i> , 2010, 341, 193-202.	1.1	4
327	In Vivo Neutralization of Unfractionated Heparin and Low-Molecular-Weight Heparin by a Novel Salicylamide Derivative. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010, 16, 377-386.	1.7	17
328	Fondaparinux (Arixtra [®]), a Safe Alternative for the Treatment of Patients With Heparin-Induced Thrombocytopenia?. <i>Journal of Pharmacy Practice</i> , 2010, 23, 235-238.	1.0	9
329	Serum Platelet Factor 4 Is an Independent Predictor of Survival and Venous Thromboembolism in Patients with Pancreatic Adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2605-2610.	2.5	55
330	Agents for the Treatment of Heparin-Induced Thrombocytopenia. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 755-775.	2.2	65
331	Established Venous Thromboembolism Therapies: Heparin, Low Molecular Weight Heparins, and Vitamin K Antagonists, with a Discussion of Heparin-Induced Thrombocytopenia. <i>Clinics in Chest Medicine</i> , 2010, 31, 691-706.	2.1	7
332	Review: Recent Advances in Argatroban-Warfarin Transition in Patients With Heparin-induced Thrombocytopenia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010, 16, 5-12.	1.7	7
333	Physiological changes in membrane-expressed platelet factor 4: Implications in heparin-induced thrombocytopenia. <i>Thrombosis Research</i> , 2010, 125, e143-e148.	1.7	9
334	Whole blood impedance aggregometry detects heparin-induced thrombocytopenia antibodies. <i>Thrombosis Research</i> , 2010, 125, e234-e239.	1.7	40
335	Clinical characteristics and laboratory testing of patients with suspected HIT: A survey on current practice in 11 university hospitals in France. <i>Thrombosis Research</i> , 2010, 125, e294-e299.	1.7	9
336	Preoperative Heparin Therapy Causes Immune-Mediated Hypotension Upon Heparin Administration for Cardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2010, 24, 69-72.	1.3	4
337	Fondaparinux: does it cause HIT? can it treat HIT?. <i>Expert Review of Hematology</i> , 2010, 3, 567-581.	2.2	81
338	Accuracy of a prediction model for heparin-induced thrombocytopenia (HIT): An analysis based on individual patient data. <i>Clinica Chimica Acta</i> , 2011, 412, 1521-1526.	1.1	5

#	ARTICLE	IF	CITATIONS
339	Performance characteristics of two commercially available IgG-specific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT). <i>Thrombosis Research</i> , 2011, 127, 345-348.	1.7	45
340	Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay. <i>Thrombosis Research</i> , 2011, 128, 256-260.	1.7	35
341	Heparin-induced thrombocytopenia (HIT) in 2011: An epidemic of overdiagnosis. <i>Thrombosis and Haemostasis</i> , 2011, 106, 993-994.	3.4	81
342	Evaluation of a new nanoparticle-based lateral-flow immunoassay for the exclusion of heparin-induced thrombocytopenia (HIT). <i>Thrombosis and Haemostasis</i> , 2011, 106, 1197-1202.	3.4	44
343	Recent advances in heparin-induced thrombocytopenia. <i>Current Opinion in Hematology</i> , 2011, 18, 315-322.	2.5	20
344	A Diagnosis of Heparin-Induced Thrombocytopenia with Combined Clinical and Laboratory Methods in Cardiothoracic Surgical Intensive Care Unit Patients. <i>Anesthesia and Analgesia</i> , 2011, 113, 697-702.	2.2	50
345	Diagnosing Heparin-Induced Thrombocytopenia in Cardiac Surgical Patients. <i>Anesthesia and Analgesia</i> , 2011, 112, 747-749.	2.2	5
347	Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2498-2500.	3.8	150
348	Heparin-induced thrombocytopenia: evaluation of IgG and IgGAM ELISA assays. <i>International Journal of Laboratory Hematology</i> , 2011, 33, 245-250.	1.3	25
349	HIT paradigms and paradoxes. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 105-117.	3.8	88
350	Review of Continuing Education Course on Hemostasis. <i>Toxicologic Pathology</i> , 2011, 39, 281-288.	1.8	8
351	Impact of laboratory testing for heparin-induced antibodies: using Bayes' rule to prevent overdiagnosis of heparin-induced thrombocytopenia/Bedeutung von Laboruntersuchungen von Heparin-induzierten Antikörpern: Einsatz des Bayes Wahrscheinlichkeitstheorems zur Prävention der Überdiagnose einer Heparin-induzierten Thrombozytopenie. <i>Laboratoriums Medizin</i> , 2011, 35, 45-54.	0.6	0
352	Rapid and simple IgG specific test for the exclusion of heparin induced thrombocytopenia (HIT). <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 2065-8.	2.3	10
353	Heparin-induced thrombocytopenia. <i>Journal of Emergencies, Trauma and Shock</i> , 2011, 4, 97.	0.7	10
354	Evaluating Heparin-Induced Thrombocytopenia: The Old and the New. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 135-143.	2.7	23
355	Heparin-Induced Thrombocytopenia: An Update. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 483-496.	2.7	49
356	Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 237-251.	2.5	39
357	A Case Series of Recombinant Platelet Factor 4 for Heparin Reversal After Cardiopulmonary Bypass. <i>Anesthesia and Analgesia</i> , 2012, 115, 1273-1278.	2.2	16

#	ARTICLE	IF	CITATIONS
358	Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients. <i>Haematologica</i> , 2012, 97, 89-97.	3.5	63
359	How I treat heparin-induced thrombocytopenia. <i>Blood</i> , 2012, 119, 2209-2218.	1.4	135
360	Rational design and characterization of platelet factor 4 antagonists for the study of heparin-induced thrombocytopenia. <i>Blood</i> , 2012, 119, 5955-5962.	1.4	34
361	Dynamic antibody-binding properties in the pathogenesis of HIT. <i>Blood</i> , 2012, 120, 1137-1142.	1.4	65
362	Adverse Effects of Heparin. <i>Handbook of Experimental Pharmacology</i> , 2012, , 211-263.	1.8	69
363	Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. <i>Blood</i> , 2012, 120, 4160-4167.	1.4	393
364	CXCL4-platelet factor 4, heparin-induced thrombocytopenia and cancer. <i>Thrombosis Research</i> , 2012, 129, S97-S100.	1.7	15
366	Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. , 2012, , CD007557.		40
367	Rapid-onset heparin-induced thrombocytopenia without previous heparin exposure. <i>Platelets</i> , 2012, 23, 495-498.	2.3	13
368	Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT. <i>Thrombosis and Haemostasis</i> , 2012, 107, 575-583.	3.4	43
369	Management of heparin-induced thrombocytopenia. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 987-1006.	1.8	11
370	Treatment and Prevention of Heparin-Induced Thrombocytopenia. <i>Chest</i> , 2012, 141, e495S-e530S.	0.8	860
371	Frequency of heparin/platelet factor 4-dependent platelet antibodies in patients undergoing angioplasty and stenting for cardiovascular disease and their role for on-clopidogrel platelet reactivity. <i>Clinical Research in Cardiology</i> , 2012, 101, 445-452.	3.3	3
372	Binding of heparin-dependent antibodies to PF4 modified by enoxaparin oligosaccharides: evaluation by surface plasmon resonance and serotonin release assay. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 430-436.	3.8	12
373	A prospective study measuring the development of antibodies against platelet factor 4-heparin in healthy males after exposure to heparins. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1446-1449.	3.8	8
374	Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 143, 1213-1218.	0.8	18
375	Interference of thrombin in immunological assays for hirudin specific antibodies. <i>Journal of Immunological Methods</i> , 2012, 381, 50-58.	1.4	4
376	Diagnosis and Management of Heparin-Induced Thrombocytopenia. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 541-563.	2.2	33

#	ARTICLE	IF	CITATIONS
378	Antiplatelet factor 4/heparin antibodies in patients with gram negative bacteremia. <i>Thrombosis Research</i> , 2013, 132, 217-220.	1.7	20
379	The skin and hypercoagulable states. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 450-462.	1.2	63
380	Refractoriness to platelet transfusion in acute myeloid leukemia correlated with the optical density of anti-platelet factor 4/heparin antibodies. <i>International Journal of Hematology</i> , 2013, 98, 472-477.	1.6	2
381	FcÎ³RIIa proteolysis as a diagnostic biomarker for heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1146-1153.	3.8	14
382	Heparin-induced thrombocytopenia: a review of concepts regarding a dangerous adverse drug reaction. <i>Revista Da Associação Médica Brasileira</i> , 2013, 59, 161-166.	0.7	16
383	Heparin-induced thrombocytopenia: a review of concepts regarding a dangerous adverse drug reaction. <i>Revista Da Associação Médica Brasileira (English Edition)</i> , 2013, 59, 161-166.	0.1	1
384	Thrombopœnies induites par lâ€™hœparine. <i>Revue Francophone Des Laboratoires</i> , 2013, 2013, 51-59.	0.0	1
385	Deep Venous Thrombosis. <i>Journal of Radiology Nursing</i> , 2013, 32, 160-164.	0.4	0
386	Nonheparin Anticoagulants for Heparin-Induced Thrombocytopenia. <i>New England Journal of Medicine</i> , 2013, 368, 737-744.	27.0	107
388	Heparin-Induced Thrombocytopenia. <i>Methods in Molecular Biology</i> , 2013, 992, 301-318.	0.9	3
390	Heparin-Induced Thrombocytopenia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013, 19, 208-214.	1.7	3
391	Heparin-induced thrombocytopenia following hip and knee arthroplasty. <i>British Journal of Haematology</i> , 2013, 161, 255-261.	2.5	13
392	Heparin-Induced Thrombocytopenia: Pathophysiology, Diagnosis, and Treatment Monitoring. <i>Drug Development Research</i> , 2013, 74, 558-567.	2.9	1
393	Murine Monoclonal Antibody to Platelet Factor 4/Heparin Complexes as a Potential Reference Standard for Platelet Activation Assays in Heparin-Induced Thrombocytopenia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013, 19, 37-41.	1.7	7
394	Novel diagnostic assays for heparin-induced thrombocytopenia. <i>Blood</i> , 2013, 121, 3727-3732.	1.4	41
395	Effects of argatroban, danaparoid, and fondaparinux on trombin generation in heparin-induced thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2013, 109, 504-509.	3.4	5
398	Characterisation of the conformational changes in platelet factor 4 induced by polyanions: towards in vitro prediction of antigenicity. <i>Thrombosis and Haemostasis</i> , 2014, 112, 53-64.	3.4	67
399	Update on argatroban for the prophylaxis and treatment of heparin-induced thrombocytopenia type II. <i>Journal of Blood Medicine</i> , 2014, 5, 131.	1.7	24

#	ARTICLE	IF	CITATIONS
400	Heparin Induced Thrombocytopenia. , 2014, , .		0
401	Micropatterned array to assess the interaction of single platelets with platelet factor 4-heparin-IgG complexes. Thrombosis and Haemostasis, 2014, 111, 862-872.	3.4	13
402	Atherosclerosis is not a risk factor for antiplatelet factor 4/heparin antibody formation after cardiopulmonary bypass surgery. Thrombosis and Haemostasis, 2014, 111, 1191-1193.	3.4	1
403	Clinical and Laboratory Diagnosis of Heparin-Induced Thrombocytopenia: An Integrated Approach. Seminars in Thrombosis and Hemostasis, 2014, 40, 106-114.	2.7	102
404	Ten-year screening for thrombocytopenia after aortic valve replacement. Interactive Cardiovascular and Thoracic Surgery, 2014, 18, 562-567.	1.1	6
405	Prospective evaluation of a rapid nanoparticle-based lateral flow immunoassay (STic) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 547 Haematology, 2014, 166, 774-782.	2.5	41
406	Current insights into the laboratory diagnosis of HIT. International Journal of Laboratory Hematology, 2014, 36, 296-305.	1.3	47
407	Anti-platelet factor 4/heparin antibodies in patients with impaired graft function after liver transplantation. Journal of Thrombosis and Haemostasis, 2014, 12, 871-878.	3.8	9
408	Structural basis of RGD-hirudin binding to thrombin: Tyr3 and five C-terminal residues are crucial for inhibiting thrombin activity. BMC Structural Biology, 2014, 14, 26.	2.3	21
409	Venous and Arterial Thrombosis. , 2014, , 277-296.		6
410	CalDAG-GEFI deficiency protects mice from Fc γ RIIa-mediated thrombotic thrombocytopenia induced by CD40L and β 2GPI immune complexes. Journal of Thrombosis and Haemostasis, 2014, 12, 2113-2119.	3.8	23
414	Low prevalence of heparin-induced thrombocytopenia after cardiac surgery in Thai patients. Thrombosis Research, 2014, 134, 957-962.	1.7	4
415	Characterization of bonds formed between platelet factor 4 and negatively charged drugs using single molecule force spectroscopy. Soft Matter, 2014, 10, 2775.	2.7	15
416	Differences in the clinical course of heparin induced thrombocytopenia before and after the availability of HIT IgG class testing. Thrombosis Research, 2014, 134, 90-92.	1.7	2
417	Amplification of bacteria-induced platelet activation is triggered by Fc γ RIIA, integrin α IIb β 3, and platelet factor 4. Blood, 2014, 123, 3166-3174.	1.4	126
418	The transfusion-related acute lung injury controversy: lessons from heparin-induced thrombocytopenia. Transfusion, 2015, 55, 1128-1134.	1.6	11
419	Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis. Blood, 2015, 125, 155-161.	1.4	79
420	Prospective evaluation of automatized α PF4/heparin immunoassays HemosIL HIT- α PF4 (HIT- α PF4) for the diagnosis of heparin-induced thrombocytopenia. International Journal of Laboratory Hematology, 2015, 37, 244-252.	1.3	13

422	Distinguishing between anti-platelet factor 4/heparin antibodies that can and cannot cause heparin-induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2015, 13, 1900-1907.	3.8	78
423	Heparin-induced thrombocytopenia. Current Opinion in Critical Care, 2015, 21, 576-585.	3.2	47
424	Clinical and laboratory characteristics associated with a high optical density anti-platelet factor 4 ELISA test. Journal of Blood Medicine, 2015, 6, 277.	1.7	2
425	Over-testing for heparin induced thrombocytopenia in hospitalized patients. Journal of Thrombosis and Thrombolysis, 2015, 40, 12-16.	2.1	20
426	Pharmacotherapy of heparin-induced thrombocytopenia: Therapeutic options and challenges in the clinical practices. Journal of Vascular Nursing, 2015, 33, 10-20.	0.7	5
427	Outcome of patients with positive heparin-platelet factor-4 antibodies: A retrospective multi-institutional observational study. Platelets, 2015, 26, 661-664.	2.3	2
428	Heparin-Induced Thrombocytopenia in Critically Ill Patients. Seminars in Thrombosis and Hemostasis, 2015, 41, 049-060.	2.7	87
429	Production of Anti-platelet Factor 4/Heparin Complex Antibodies After Cardiovascular Surgery. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 177-180.	1.7	3
430	Quantitative description of thermodynamic and kinetic properties of the platelet factor 4/heparin bonds. Nanoscale, 2015, 7, 10130-10139.	5.6	46
431	Deep Venous Thrombosis. , 2015, , 135-149.		0
432	Current management of heparin-induced thrombocytopenia. Expert Review of Hematology, 2015, 8, 837-849.	2.2	11
433	Novel HIT antibody detection method using Sonoclot® coagulation analyzer. Thrombosis Research, 2015, 135, 127-129.	1.7	2
434	Rivaroxaban in treatment refractory heparin-induced thrombocytopenia. BMJ Case Reports, 2016, 2016, bcr2016216110.	0.5	7
435	Vitrectomy for Proliferative Diabetic Retinopathy in a Patient with Heparin-Induced Thrombocytopenia. Case Reports in Ophthalmology, 2016, 7, 67-73.	0.7	2
436	Clinical and laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Thrombosis and Haemostasis, 2016, 116, 823-834.	3.4	41
437	Role of monocytes and endothelial cells in heparin-induced thrombocytopenia. Thrombosis and Haemostasis, 2016, 116, 806-812.	3.4	15
438	Diagnostic accuracy of rapid immunoassays for heparin-induced thrombocytopenia. Thrombosis and Haemostasis, 2016, 115, 1044-1055.	3.4	56

#	ARTICLE	IF	CITATIONS
439	Management of the multiple phases of heparin-induced thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2016, 116, 835-842.	3.4	43
440	Safe bridging to warfarin in heparin-induced thrombocytopenia. <i>Thrombosis Research</i> , 2016, 144, 226-228.	1.7	0
441	Platelet Factor 4 Inhibits and Enhances HIV-1 Infection in a Concentration-Dependent Manner by Modulating Viral Attachment. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 705-717.	1.1	21
442	Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia. <i>Blood</i> , 2016, 127, 464-472.	1.4	86
443	Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis. <i>Blood</i> , 2016, 127, 546-557.	1.4	112
444	Acute intraoperative heparin-induced thrombocytopenia (HIT) and thrombosis during coronary artery bypass grafting: Two case reports providing evidence for the role of preoperative LMWH in triggering sensitization. <i>Thrombosis Research</i> , 2016, 146, 126-130.	1.7	5
445	Bullous dermatosis at distant sites in patients treated with heparin. <i>Medicina Clínica (English)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 502 0,2	0.2	2
447	Thrombocytopenia. <i>Primary Care - Clinics in Office Practice</i> , 2016, 43, 543-557.	1.6	35
448	Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2016, 116, 813-822.	3.4	69
449	An update on heparin-induced thrombocytopenia: diagnosis and management. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 787-797.	2.4	10
450	A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis. <i>Chest</i> , 2016, 150, 506-515.	0.8	80
452	Profile of Instrumentation Laboratory's HemosIL® AcuStar HIT-Ab(PF4-H) assay for diagnosis of heparin-induced thrombocytopenia. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 419-426.	3.1	11
454	Diagnostic accuracy of IgG-specific versus polyspecific enzyme-linked immunoassays in heparin-induced thrombocytopenia: a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1203-1212.	3.8	32
455	Heparin-induced thrombocytopenia. <i>Blood</i> , 2017, 129, 2864-2872.	1.4	319
456	Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients. <i>The Cochrane Library</i> , 2017, 2017, CD007557.	2.8	64
457	Heparin-Induced Thrombocytopenia in Cardiac Surgery Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 691-698.	2.7	48
458	Inappropriate documentation of heparin allergy in the medical record because of misdiagnosis of heparin-induced thrombocytopenia: frequency and consequences. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 370-374.	3.8	15
459	Heparan sulfate/heparin glycosaminoglycan binding alters inhibitory profile and enhances anticoagulant function of conserved <i>Amblyomma americanum</i> tick saliva serpin 19. <i>Insect Biochemistry and Molecular Biology</i> , 2017, 80, 1-10.	2.7	27

#	ARTICLE	IF	CITATIONS
460	PF4-HIT antibody (KKO) complexes activate broad innate immune and inflammatory responses. <i>Thrombosis Research</i> , 2017, 159, 39-47.	1.7	14
461	A Platelet Factor 4-Dependent Platelet Activation Assay Facilitates Early Detection of Pathogenic Heparin-Induced Thrombocytopenia Antibodies. <i>Chest</i> , 2017, 152, e77-e80.	0.8	20
462	Beneficial effect of exogenous platelet factor 4 for detecting pathogenic heparin-induced thrombocytopenia antibodies. <i>British Journal of Haematology</i> , 2017, 179, 811-819.	2.5	51
463	Implementation of a rapid HIT immunoassay at a university hospital – Retrospective analysis of HIT laboratory orders in patients with thrombocytopenia. <i>Thrombosis Research</i> , 2017, 158, 65-70.	1.7	1
464	Spontaneous HIT syndrome post-knee replacement surgery with delayed recovery of thrombocytopenia: a case report and literature review. <i>Platelets</i> , 2017, 28, 614-620.	2.3	51
465	Impact of pneumatic tube system transport for the monitoring of heparin therapy. <i>Thrombosis Research</i> , 2017, 158, 35-37.	1.7	1
466	HITs and misses in 100 years of heparin. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 667-673.	2.5	8
468	Platelets kill bacteria by bridging innate and adaptive immunity via platelet factor 4 and Fcγ3RIIA. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1187-1197.	3.8	64
469	Heparin-Induced Thrombocytopenia in the Critically Ill Patient. <i>Chest</i> , 2018, 154, 678-690.	0.8	26
470	Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1402-1412.	3.8	8
471	Platelet response to direct thrombin inhibitor or fondaparinux treatment in patients with suspected heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 536-542.	2.1	4
472	Activated Platelet-Derived and Leukocyte-Derived Circulating Microparticles and the Risk of Thrombosis in Heparin-Induced Thrombocytopenia: A Role for PF4-Bearing Microparticles?. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 334-341.	1.5	34
473	Anticoagulant-Free Off-Pump Left Ventricular Assist Device Implant. <i>Annals of Thoracic Surgery</i> , 2018, 105, e37-e39.	1.3	10
474	American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. <i>Blood Advances</i> , 2018, 2, 3360-3392.	5.2	448
475	Profiling Heparin-Induced Thrombocytopenia (HIT) Antibodies in Hospitalized Patients With and Without Diabetes. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 294S-300S.	1.7	5
476	Hemostatic Abnormalities in the Critically Ill. , 2018, , 17-39.		0
477	An update on evidence based diagnostic and confirmatory testing strategies for heparin induced thrombocytopenia using combined immunological and functional assays. <i>Transfusion and Apheresis Science</i> , 2018, 57, 804-811.	1.0	7
478	Moving target PF4 directs HIT responses. <i>Blood</i> , 2018, 132, 678-679.	1.4	1

#	ARTICLE	IF	CITATIONS
479	Hematologic Disorders. Anesthesiology Clinics, 2018, 36, 553-565.	1.4	4
480	Heparin-induced thrombocytopenia complicating extracorporeal membrane oxygenation support in pediatric patients: review of the literature and alternative anticoagulants. Perfusion (United Tj ETQq1 1 0.784314 ngB /Overlock 10 Tf	1.4	10
481	Characterization of hospitalized cardiovascular patients with suspected heparin-induced thrombocytopenia. Clinical Cardiology, 2018, 41, 1521-1526.	1.8	8
482	Dynamic intercellular redistribution of HIT antigen modulates heparin-induced thrombocytopenia. Blood, 2018, 132, 727-734.	1.4	9
483	High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. Expert Review of Hematology, 2019, 12, 685-698.	2.2	121
484	A platelet viability assay (PVA) for the diagnosis of heparin-induced thrombocytopenia. Platelets, 2019, 30, 1017-1021.	2.3	6
485	Neutrophil and Monocyte Counts in Heparin-Induced Thrombocytopenia. Thrombosis and Haemostasis, 2019, 119, 941-951.	3.4	9
487	Evaluation of heparin induced thrombocytopenia using probability scores in a mechanical circulatory support population. Journal of Thrombosis and Thrombolysis, 2019, 48, 134-140.	2.1	8
488	Heparinoids Danaparoid and Sulodexide as clinically used drugs. Progress in Molecular Biology and Translational Science, 2019, 163, 55-74.	1.7	19
490	Fibronectin modulates formation of PF4/heparin complexes and is a potential factor for reducing risk of developing HIT. Blood, 2019, 133, 978-989.	1.4	14
491	Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2019, 17, 389-399.	3.8	33
493	The use of flow cytometry in the diagnosis of heparin-induced thrombocytopenia (HIT). Transfusion Medicine Reviews, 2020, 34, 34-41.	2.0	4
494	Thrombocytopenia and thrombocytosis. , 2020, , 695-719.		1
495	Serotonin release assay-negative heparin-induced thrombocytopenia. American Journal of Hematology, 2020, 95, 38-47.	4.1	43
496	Measurement of blood activation markers applied to the early diagnosis of cardiovascular alterations. Expert Review of Molecular Diagnostics, 2020, 20, 85-98.	3.1	3
497	Extracellular DNA "A Danger Signal Triggering Immunothrombosis. Frontiers in Immunology, 2020, 11, 568513.	4.8	33
498	Challenges in Detecting Clinically Relevant Heparin-Induced Thrombocytopenia Antibodies. Hamostaseologie, 2020, 40, 472-484.	1.9	11
499	SARS-CoV-2 and pulmonary embolism: who stole the platelets?. Thrombosis Journal, 2020, 18, 16.	2.1	11

#	ARTICLE	IF	CITATIONS
500	<p>Current Perspectives on Diagnostic Assays and Anti-PF4 Antibodies for the Diagnosis of Heparin-Induced Thrombocytopenia</p>. Journal of Blood Medicine, 2020, Volume 11, 267-277.	1.7	15
501	Targeting Biological Polyanions in Blood: Strategies toward the Design of Therapeutics. Biomacromolecules, 2020, 21, 2595-2621.	5.4	7
502	Evolving concepts of pathogenesis of heparin-induced thrombocytopenia: Diagnostic and therapeutic implications. International Journal of Laboratory Hematology, 2020, 42, 25-32.	1.3	13
503	Rivaroxaban as an Alternative Agent for Heparin-Induced Thrombocytopenia. Journal of Clinical Pharmacology, 2020, 60, 1362-1366.	2.0	11
504	Comparative Analysis of a French Prospective Series of 144 Patients with Heparin-Induced Thrombocytopenia (FRIGTIH) and the Literature. Thrombosis and Haemostasis, 2020, 120, 1096-1107.	3.4	29
505	Update on Mechanisms, Pathogenicity, Heterogeneity of Presentation, and Laboratory Diagnosis of Heparin-Induced Thrombocytopenia. , 0, , .		3
506	Heparin-induced thrombocytopenia: Diagnostic challenges in intensive care patients especially with extracorporeal circulation. Thrombosis Research, 2020, 188, 52-60.	1.7	11
507	The role of fluid-phase immune complexes in the pathogenesis of heparin-induced thrombocytopenia. Thrombosis Research, 2020, 194, 135-141.	1.7	5
508	Bleeding, Heparin-induced thrombocytopenia, and Other adverse reactions. , 2020, , 147-187.		0
509	Diagnosis and management of heparin-induced thrombocytopenia. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 291-310.	1.4	45
510	Factors influencing activated clotting time following heparin administration for the initiation of cardiopulmonary bypass. General Thoracic and Cardiovascular Surgery, 2021, 69, 38-43.	0.9	5
511	Construction of heparan sulfate microarray for investigating the binding of specific saccharide sequences to proteins. Glycobiology, 2021, 31, 188-199.	2.5	16
512	Off-target binding of an anti-amyloid beta monoclonal antibody to platelet factor 4 causes acute and chronic toxicity in cynomolgus monkeys. MABs, 2021, 13, 1887628.	5.2	8
513	Intraoperative collection of autologous platelet-rich plasma from the cardiopulmonary bypass circuit upon initiation of extracorporeal circulation. Journal of Cardiothoracic Surgery, 2021, 16, 17.	1.1	0
514	An Optimized and Standardized Rapid Flow Cytometry Functional Method for Heparin-Induced Thrombocytopenia. Biomedicines, 2021, 9, 296.	3.2	6
515	Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment. Expert Review of Hematology, 2021, 14, 335-346.	2.2	12
516	Heparin-induced thrombocytopenia. Cmaj, 2021, 193, E736-E736.	2.0	29
517	Understanding VITT(ual) reality. Blood, 2021, 138, 285-286.	1.4	2

#	ARTICLE	IF	CITATIONS
518	P-selectin expression assay in a repeatedly serotonin-release assay-negative patient with heparin-induced thrombocytopenia. Blood Coagulation and Fibrinolysis, 2021, Publish Ahead of Print, 522-525.	1.0	1
519	Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia. Thrombosis Research, 2021, 204, 40-51.	1.7	72
520	Low ADAMTS-13 predicts adverse outcomes in hospitalized patients with suspected heparin-induced thrombocytopenia. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12581.	2.3	5
521	Heparin-induced Thrombocytopenia Diagnosis: A Retrospective Study Comparing Heparin-induced Platelet Activation Test to 14C-serotonin Release Assay. TH Open, 2021, 05, e507-e512.	1.4	5
523	Hematologic Emergencies. , 2022, , 121-145.		0
524	Immunology of Leucocytes, Platelets and Plasma Components. , 0, , 546-610.		1
525	Laboratory Methods and Management of Patients with Heparin-Induced Thrombocytopenia. Methods in Molecular Biology, 2010, 663, 133-156.	0.9	3
526	Heparin-induzierte Thrombozytopenie. , 1999, , 83-94.		1
527	Transfusion Medicine and Coagulation Disorders. , 2011, , 949-991.		3
528	The molecular basis of immune-based platelet disorders. Clinical Science, 2020, 134, 2807-2822.	4.3	1
531	Heparin-Associated Thrombocytopenia: The Effects of Various Intravenous IgG Preparations on Antibody Mediated Platelet Activation - A Possible New Indication for High Dose i.v. IgG. Thrombosis and Haemostasis, 1994, 71, 641-645.	3.4	81
532	Characterization of the Structural Requirements for a Carbohydrate Based Anticoagulant with a Reduced Risk of Inducing the Immunological Type of Heparin-associated Thrombocytopenia. Thrombosis and Haemostasis, 1995, 74, 886-892.	3.4	139
533	Antibodies to Macromolecular Platelet Factor 4-Heparin Complexes in Heparin-induced Thrombocytopenia: a Study of 44 Cases. Thrombosis and Haemostasis, 1995, 73, 021-028.	3.4	243
535	Prevalence and Persistence of Heparin/Platelet Factor 4 Antibodies in Patients with Heparin Coated and Noncoated Ventricular Assist Devices. ASAIO Journal, 2000, 46, 319-322.	1.6	39
536	THE ???WHITE CLOT SYNDROME??? IN HEPATIC TRANSPLANTATION. Transplantation, 1996, 61, 982-984.	1.0	7
537	INHIBITOR AGAINST COAGULATION FACTOR V AFTER LIVER TRANSPLANTATION. Transplantation, 1999, 68, 1054-1056.	1.0	20
538	NEW APPROACH FOR DETECTION OF HEPARIN DEPENDENT ANTIBODIES AND RISK ASSESSMENT FOR HEPARIN INDUCED THROMBOCYTOPENIA. Journal of Thrombosis and Haemostasis, 2007, 5, P-T-319-P-T-319.	3.8	2
539	Management of Deep Vein Thrombosis and Pulmonary Embolism. Circulation, 1996, 93, 2212-2245.	1.6	553

#	ARTICLE	IF	CITATIONS
540	Prevalence of Heparin-Associated Antibodies Without Thrombosis in Patients Undergoing Cardiopulmonary Bypass Surgery. <i>Circulation</i> , 1997, 95, 1242-1246.	1.6	293
541	Relationship between Platelet Aggregatory and Heparin-Induced Thrombocytopenia Type II. <i>Science Research</i> , 2014, 2, 78.	0.2	1
542	Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.. <i>Journal of Clinical Investigation</i> , 1994, 93, 81-88.	8.2	504
543	Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia. <i>Journal of Clinical Investigation</i> , 2017, 127, 1090-1098.	8.2	37
544	Drug-Induced Thrombophilic or Prothrombotic States: An Underestimated Clinical Problem That Involves Both Legal and Illegal Compounds. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 775-785.	1.7	14
546	Heparin-Induced Thrombocytopenia: New Insights Into the Impact of the Fc γ RIIIa-R-H131 Polymorphism. <i>Blood</i> , 1998, 92, 1526-1531.	1.4	3
547	Defining an Antigenic Epitope on Platelet Factor 4 Associated With Heparin-Induced Thrombocytopenia. <i>Blood</i> , 1998, 92, 3250-3259.	1.4	7
548	Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. <i>Blood</i> , 2000, 96, 188-194.	1.4	10
549	Impact of the patient population on the risk for heparin-induced thrombocytopenia. <i>Blood</i> , 2000, 96, 1703-1708.	1.4	22
550	Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. <i>Blood</i> , 2000, 96, 2373-2378.	1.4	1
552	Role of Sulfated Polysaccharides in the Pathogenesis of Heparin- Induced Thrombocytopenia. , 2003, , .		7
553	Expression, Purification, and Mass Spectrometric Analysis of 15N, 13C-Labeled RGD-Hirudin, Expressed in <i>Pichia pastoris</i> , for NMR Studies. <i>PLoS ONE</i> , 2012, 7, e42207.	2.5	9
554	Endovascular Repair of an Extracranial Internal Carotid Artery Aneurysm Complicated by Heparin-Induced Thrombocytopenia and Thrombosis. <i>Journal of Endovascular Therapy</i> , 2000, 7, 353-358.	1.5	8
555	Detection and identification of platelet antibodies and antigens in the clinical laboratory. <i>Immunohematology</i> , 2009, 25, 125-135.	0.2	41
556	New Oral Anticoagulants for the Management of Heparin Induced Thrombocytopenia: A Focused Literature Review. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2015, 13, 87-91.	1.0	8
557	Open-heart surgery in a patient with severe heart failure with heparin-induced thrombocytopenia. <i>Chirurgia (Turin)</i> , 2020, 33, .	0.1	1
558	Heparin-induced thrombocytopenia: ELISA optical density value and 4T score in correlation with panel donor platelets activation in functional flow cytometric assay. <i>Blood Transfusion</i> , 2021, 19, 77-84.	0.4	2
559	Heparin-Induced Thrombocytopenia and Treatment with Thrombin Inhibitors. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2005, 16, 623-640.	0.1	2

#	ARTICLE	IF	CITATIONS
560	History of Heparin-Induced Thrombocytopenia. Fundamental and Clinical Cardiology, 2007, , 1-20.	0.0	2
561	Nonimmune Heparin-Platelet Interactions: Implications for the Pathogenesis of Heparin-Induced Thrombocytopenia. Fundamental and Clinical Cardiology, 2007, , 117-130.	0.0	3
562	Role of Heparin-Dependent Antigens in Immune Heparin-Induced Thrombocytopenia. Fundamental and Clinical Cardiology, 2007, , 131-148.	0.0	1
563	Role of Sulfated Polysaccharides in the Pathogenesis of Heparin-Induced Thrombocytopenia. Fundamental and Clinical Cardiology, 2007, , 167-186.	0.0	4
564	Platelet and Leukocyte Fc γ Receptors in Heparin-Induced Thrombocytopenia. Fundamental and Clinical Cardiology, 2007, , 187-208.	0.0	3
565	Laboratory Testing for Heparin-Induced Thrombocytopenia. Fundamental and Clinical Cardiology, 2007, , 227-260.	0.0	17
566	Pathophysiology of Heparin-Induced Thrombocytopenia. Archives of Pathology and Laboratory Medicine, 2000, 124, 1657-1666.	2.5	58
567	Platelet Count Monitoring and Laboratory Testing for Heparin-Induced Thrombocytopenia. Archives of Pathology and Laboratory Medicine, 2002, 126, 1415-1423.	2.5	124
568	Investigations of the Immunoglobulin Subtype Transformation of Anti-Heparin-Platelet Factor 4 Antibodies During Treatment With a Low-Molecular-Weight Heparin (Clivarin) in Orthopedic Patients. Archives of Pathology and Laboratory Medicine, 2003, 127, 584-588.	2.5	13
569	Dabigatran use after argatroban for heparin-induced thrombocytopenia with thrombosis: A case series and literature review. Annals of Vascular Surgery, 2021, , .	0.9	1
570	Lupus Anticoagulants: Mechanistic and Diagnostic Considerations. , 2000, , 225-237.		0
571	Principles in Hemostasis. , 2000, , 1201-1223.		0
573	Venous Disease and Pulmonary Embolism. , 2001, , 1083-1109.		0
574	抗血小板薬の副作用. Japanese Journal of Thrombosis and Hemostasis, 2002, 82, 284-288.		
575	抗血小板薬の副作用. Japanese Journal of Thrombosis and Hemostasis, 2002, 82, 284-288.		
576	Zur Problematik des akuten arteriellen Verschlusses als Folge einer heparininduzierten Thrombozytopenie. Berliner Gefäßchirurgische Reihe, 2002, , 69-77.	0.0	0
577	A case of heparin-induced thrombocytopenia with multiple thrombosis concomitant with various allergic manifestations.. Nihon Toseki Igakkai Zasshi, 2003, 36, 1343-1348.	0.1	0
578	Anticoagulant therapy. , 2003, , 157-165.		0

#	ARTICLE	IF	CITATIONS
581	A case with combined multiple retina thrombosis probably due to heparin-induced thrombocytopenia (HIT). Nihon Toseki Igakkai Zasshi, 2004, 37, 1437-1442.	0.1	0
583	Heparin Induced Thrombocytopenia. , 2007, , 1-4.		0
586	Molecular Immunopathogenesis of Heparin-Induced Thrombocytopenia. Fundamental and Clinical Cardiology, 2007, , 149-166.	0.0	1
587	Venous Disease and Pulmonary Embolism. , 2008, , 1429-1456.		1
588	Heparin-induced Thrombocytopenia (HIT)(1. Systemic Complications Neurosurgeons need to) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 587 2008, 17, 909-916.	0.0	1
589	Heparin-induced Thrombocytopenia (HIT). Nosotchu, 2008, 30, 960-966.	0.1	1
590	Improving Blood Compatibility of Biomaterials Using a Novel Antithrombin-Heparin Covalent Complex. , 2008, , 535-572.		0
592	HIT-Diagnostik. , 2010, , 857-860.		0
593	Hematologic Disorders in the Elderly. , 2011, , 207-219.		0
594	Heparin-induced thrombocytopenia type II in a patient who underwent rectal cancer surgery. Nihon Daicho Komonbyo Gakkai Zasshi, 2012, 65, 26-30.	0.0	0
596	Recent advances in the pathogenesis, diagnosis, and treatment of immune heparin-induced thrombocytopenia. Japanese Journal of Thrombosis and Hemostasis, 2012, 23, 362-374.	0.1	3
598	Why Is the Platelet Count Low: Should I Be Concerned About Heparin-Induced Thrombocytopenia?. Journal of Pediatric Pharmacology and Therapeutics, 2012, 17, 2-6.	0.5	12
599	Murine models of heparin-induced thrombocytopenia. , 2012, , 264-283.		0
600	Heparin-induced thrombocytopenia (HIT) in hemodialysis patients experienced in our hospital. Nihon Toseki Igakkai Zasshi, 2013, 46, 1075-1081.	0.1	0
603	Thrombocytopenia in the Intensive Care Unit and After Solid Organ Transplantation. , 2014, , 115-132.		1
604	Coagulation in Kidney Disease. , 2014, , 603-612.		0
605	Early Graft Dysfunction Post Coronary Artery Bypass due to Heparin Induced Thrombocytopenic Thrombosis. IOSR Journal of Dental and Medical Sciences, 2014, 13, 13-16.	0.0	0
606	Hematologic Complications of Transplantation. , 2014, , 235-245.		0

#	ARTICLE	IF	CITATIONS
607	Akute Gefäßverschlüsse – interdisziplinäres Therapiespektrum. , 1995, , 1030-1066.		0
608	Die Heparin-induzierte Thrombozytopenie. , 1996, , 71-77.		0
609	Heparin-associated Autoantibodies. , 1996, , 343-350.		0
610	Heparin as a cause of thrombus progression. European Journal of Pediatrics, 1996, 155, 11-14.	2.7	30
612	Hämostaseologie und Einflussfaktoren auf Entstehung und Verlauf von Gefäßkrankheiten. , 1997, , 57-67.		0
614	Adenosine Diphosphate (ADP) and ADP Receptor Play a Major Role in Platelet Activation/Aggregation Induced by Sera From Heparin-Induced Thrombocytopenia Patients. Blood, 1998, 91, 549-554.	1.4	0
615	Platelet Fc receptors for IgG and IgE. , 1998, , 119-134.		1
616	Antibodies From Patients With Heparin-Induced Thrombocytopenia/Thrombosis Recognize Different Epitopes on Heparin: Platelet Factor 4. Blood, 1998, 91, 916-922.	1.4	0
617	Early Onset of Immunological Heparin-Induced Thrombocytopenia in Acute Myocardial Infarction and Anti-Platelet Factor 4-Heparin Complex Antibody.. Japanese Journal of Thrombosis and Hemostasis, 1999, 10, 106-110.	0.1	0
618	Pathophysiologie und Therapie der heparininduzierten Thrombozytopenie: Warum sind Antikoagulanzen mit Antithrombinaktivität sinnvoll bei HIT?. , 1999, , 101-115.		0
619	Heparin and Other Indirect Antithrombin Agents. Handbook of Experimental Pharmacology, 1999, , 259-303.	1.8	0
621	Anticoagulant Managements of Left Ventricular Assist Device Implantation in Two Patients with Heparin-Induced Thrombocytopenia (HIT): Use of Argatroban as an Anticoagulant for Cardiopulmonary Bypass. Journal of Anesthesia & Clinical Research, 2015, 06, .	0.1	0
622	Heparin-Induced Thrombocytopenia: Diagnosis and Management. , 2016, , 519-529.		0
623	Treatment of Heparin-Induced Thrombocytopenia. , 2016, , 291-310.		1
624	Risk factors for venous thromboembolism in women. Reproductive Endocrinology, 2018, .	0.3	0
625	Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia. American Journal of Case Reports, 2020, 21, e922498.	0.8	2
626	Platelet antibodies in immune thrombocytopenia and related conditions. Journal of Laboratory Medicine, 2020, 44, 273-284.	1.1	7
627	Argatroban as Purge Solution in Patients With Heparin-Induced Thrombocytopenia on an Impella Device, a Case Review. American Journal of Therapeutics, 2020, Publish Ahead of Print, e763-e765.	0.9	4

#	ARTICLE	IF	CITATIONS
630	The path of uncovering a prothrombotic thrombocytopenic syndrome after viral vectorâ€based COVIDâ€19 vaccination: Where there is much light, the shadow is deep. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12609.	2.3	1
631	Measurement of procoagulant platelets provides mechanistic insight and diagnostic potential in heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2022, 20, 975-988.	3.8	17
632	Cost-effectiveness analysis of alternative anticoagulation in suspected heparin-induced thrombocytopenia. Blood Advances, 2022, 6, 3114-3125.	5.2	1
634	Platelet-activating anti-PF4 disorders: An overview. Seminars in Hematology, 2022, 59, 59-71.	3.4	25
635	Laboratory testing for VITT antibodies. Seminars in Hematology, 2022, 59, 80-88.	3.4	11
636	Similarities of antiphospholipid antibodies in HIT and APS patients with heparin-platelet factor 4 antibodies. Thrombosis Update, 2022, , 100106.	0.9	0
637	Rare presentation of enoxaparin-induced skin necrosis in a postoperative patient. BMJ Case Reports, 2022, 15, e249685.	0.5	3
638	A Case of Heparin-induced Thrombocytopenia after Surgery for Esophageal Cancer. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2021, 46, 120-125.	0.0	0
639	The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia. Blood Advances, 2022, 6, 4228-4235.	5.2	18
640	Reducing Delayed Diagnosis and Overtreatment in Heparin-Induced Thrombocytopenia by Using a Machine-Learning Model: A Prospective, Multicenter, Observational Study. SSRN Electronic Journal, 0, , .	0.4	0
641	Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications. Cells, 2022, 11, 3214.	4.1	17
642	Vaccine-induced immune thrombotic thrombocytopenia: Updates in pathobiology and diagnosis. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	5
643	A machine-learning model for reducing misdiagnosis in heparin-induced thrombocytopenia: a prospective, multicenter, observational study. EClinicalMedicine, 2023, 55, 101745.	7.1	8
644	Laboratory Testing for Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia Antibodies: A Narrative Review. Seminars in Thrombosis and Hemostasis, 2023, 49, 621-633.	2.7	12
645	Mechanisms of Thrombosis in Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia. Seminars in Thrombosis and Hemostasis, 2023, 49, 444-452.	2.7	6
646	Functional Testing for Heparin-Induced Thrombocytopenia Using Whole Blood Multiplate Impedance Aggregometry. Methods in Molecular Biology, 2023, , 417-428.	0.9	0
647	Whole Blood Procoagulant Platelet Flow Cytometry Protocol for Heparin-Induced Thrombocytopenia (HIT) and Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Testing. Methods in Molecular Biology, 2023, , 441-461.	0.9	1
648	Platelet factor 4 triggers thromboâ€inflammation by bridging innate and adaptive immunity. International Journal of Laboratory Hematology, 2023, 45, 11-22.	1.3	7

#	ARTICLE	IF	CITATIONS
649	Platelet phosphatidylserine is the critical mediator of thrombosis in heparin-induced thrombocytopenia. <i>Haematologica</i> , 2023, 108, 2690-2702.	3.5	4
650	Novel Knowledge about Molecular Mechanisms of Heparin-Induced Thrombocytopenia Type II and Treatment Targets. <i>International Journal of Molecular Sciences</i> , 2023, 24, 8217.	4.1	2
651	Investigation of anti-PF4 versus anti-PF4/heparin reactivity using fluid-phase enzyme immunoassay for 4 anti-PF4 disorders: classic heparin-induced thrombocytopenia (HIT), autoimmune HIT, vaccine-induced immune thrombotic thrombocytopenia, andÂspontaneous HIT. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 2268-2276.	3.8	15
652	Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)â€”Insights from Clinical Cases, In Vitro Studies and Murine Models. <i>Journal of Clinical Medicine</i> , 2023, 12, 6126.	2.4	0
653	The immunology of PF4 polyanion interactions. <i>Current Opinion in Hematology</i> , 2023, 30, 219-229.	2.5	1
654	Heparin-induced thrombosis with a normal platelet count. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2007, 9, 51-54.	0.1	0
655	Heparin-induced Thrombocytopenia with Anaphylactoid Reaction during Hemodialysis. <i>Internal Medicine</i> , 2024, , .	0.7	1
656	PF4 activates the c-Mplâ€”Jak2 pathway in platelets. <i>Blood</i> , 2024, 143, 64-69.	1.4	2
657	A career in solving clinicalâ€”pathological conundrums: <scp>Heyde syndrome</scp>, antiâ€”platelet factor 4 disorders, and microvascular limb ischemic necrosis. <i>International Journal of Laboratory Hematology</i> , 0, , .	1.3	0